There was little evidence to support associations of genetic liability to type 2 diabetes, parity, or circulating levels of 25-hydroxyvitamin D or sex hormone binding globulin with the various ovarian cancer outcomes assessed. This evidence concerns the gene SHBG and type 2 diabetes mellitus.